Subtype
Bladder Carcinoma
CI-CAN-00007316Explore in graph →
141 active trials7 approved drugs19 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007316Explore in graph →
Clinical trials
332 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (49)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05014139 | A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC) | terminated | Phase 1 | 37 | Astellas Pharma Global Development, Inc.INDUSTRY | 6 | Sep 14, 2026 | clinicaltrials |
| NCT02106572 | Therapeutic Instillation of Mistletoe(TIM) | terminated | Phase 3 | 174 | Abnoba GmbhINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT03324282 | First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma(GCISAVE) | terminated | Phase 2 | 65 | University Hospital, BordeauxOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04902040 | Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | terminated | Phase 1 / Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05581589 | Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer | terminated | Phase 2 | 4 | University of WashingtonOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05700227 | Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer(ARTIA-Bladder) | terminated | N/A | 2 | Varian, a Siemens Healthineers CompanyINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT01495676 | A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer(GETUGV04) | terminated | N/A | 69 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT04985604 | Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors | terminated | Phase 2 | 23 | Day One Biopharmaceuticals, Inc.INDUSTRY | 7 | Oct 2, 2025 | clinicaltrials |
| NCT05248789 | OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer | terminated | Phase 2 | 4 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | terminated | Phase 2 | 40 | Rain Oncology IncINDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT05363605 | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | terminated | Phase 1 / Phase 2 | 6 | Fusion Pharmaceuticals Inc.INDUSTRY | 2 | Dec 19, 2023 | clinicaltrials |
| NCT01215136 | First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma | terminated | Phase 2 | 36 | Matthew GalskyOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT06069453 | Hyaluronic Acid Sodium Salt and Hydeal-D in the Management of LUTS After TURBT for NMIBC. | terminated | N/A | 54 | Fidia Farmaceutici s.p.a.INDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT03912818 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer | terminated | Phase 2 | 7 | Stanford UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT03397394 | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma(ATLAS) | terminated | Phase 2 | 97 | pharmaand GmbHINDUSTRY | 6 | Jun 9, 2023 | clinicaltrials |
| NCT05221827 | Clinical Performance Evaluation of the C2i-Test | terminated | — | 3 | C2i GenomicsINDUSTRY | 1 | Feb 27, 2023 | clinicaltrials |
| NCT05052372 | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib | terminated | — | 2 | xCuresINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT02901548 | Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder | terminated | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT03266900 | A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival(RESECT) | terminated | Early Phase 1 | 2 | University Health Network, TorontoOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT03549650 | Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms | terminated | Phase 2 | 3 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT01954173 | Adjuvant Radiation for High Risk Bladder Cancer | terminated | N/A | 19 | Emory UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT02767921 | sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer | terminated | Phase 1 | 2 | University of Southern CaliforniaOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT03719300 | Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC | terminated | Phase 2 | 32 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 1 | Aug 19, 2020 | clinicaltrials |
| NCT03167151 | Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)(PemBla) | terminated | Phase 1 / Phase 2 | 6 | University of OxfordOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT02169284 | Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03335059 | Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.(RITE-USA) | terminated | Phase 3 | 5 | Medical Enterprises Ltd.INDUSTRY | 1 | Apr 15, 2020 | clinicaltrials |
| NCT01611662 | Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | terminated | Phase 2 | 32 | Fox Chase Cancer CenterOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT02494635 | Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer | terminated | — | 4 | University of Southern CaliforniaOTHER | 1 | Jul 8, 2019 | clinicaltrials |
| NCT02202044 | Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection | terminated | N/A | 13 | University of Colorado, DenverOTHER | 1 | Jun 14, 2019 | clinicaltrials |
| NCT02699853 | Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer | terminated | N/A | 1 | University of Southern CaliforniaOTHER | 1 | May 3, 2019 | clinicaltrials |
| NCT02145390 | Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy | terminated | N/A | 1 | University of MiamiOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy | terminated | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | terminated | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT01245660 | A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy(LAPAINBLAD) | terminated | Early Phase 1 | 3 | University Hospital, BordeauxOTHER | 1 | Jan 11, 2013 | clinicaltrials |
Data updated 15 days agoSource updated Sep 14, 2026source: clinicaltrials